Skip to main content
OpenTrials
Completed

NCT Number: NCT01149733

Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions

The objective of this study is to evaluate the comparative bioavailability between tamsulosin hydrochloride 0.4 mg capsules (Manufactured by Teva Pharmaceutical Industries Ltd.; distributed by Teva Pharmaceuticals USA) and Flomax® (tamsulosin hydrochloride)0.4 mg capsules (Manufactured by Yamanouchi Pharmaceutical Co., Japan; distributed by Boehringer Ingelheim Pharmaceutical Inc. USA), after a single-dose in healthy subjects under fed conditions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Pharma Medica Research Inc.

Toronto, Ontario, M1R 5A3, Canada

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy, non-smoking male subjects, 18 years of age or older.
  • BMI greater than or equal to 19 and less than or equal to 30.
  • Negative for:
  • HIV.
  • Hepatitis B surface antigen and Hepatitis C antibody.
  • Using drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone).
  • Urine cotinine test
  • No significant diseases or clinically significant findings in a physical examination.
  • No clinically significant abnormal laboratory values.
  • No clinically significant findings in vital signs measurements and a 12-lead electrocardiogram (ECG).
  • Systolic blood pressure between 100-140 mmHg and diastolic blood pressure between 60-90 mmgHg.
  • Be informed of the nature of the study and given written consent prior to receiving any study procedure.

Exclusion criteria

  • Known history or presence of any clinically significant medical condition, illness or surgery within 4 weeks prior to drug administration.
  • Known or suspected carcinoma.
  • Known history or presence of:
  • Hypersensitivity or idiosyncratic reaction to tamsulosin and/or any other drug substances with similar activity.
  • Alcoholism within the last 12 months.
  • Drug dependence and/or substance abuse.
  • Use of tobacco or nicotine-containing products within the last 6 months.
  • Use of any prescription medication within 14 days prior to Period 1 dosing. Use of any over the counter (OTC) medication within 7 days prior to Period 1 dosing.
  • Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to Period 1 dosing.
  • On a special diet within 4 weeks prior to drug administration (e.g. liquid, protein, raw food diet).
  • Participated in another clinical trial or received and investigational product within 30 days prior to drug administration.
  • Donated up to 250 mL of blood within the previous 30 days OR Donated from 251 to 500 mL of blood in the previous 45 days OR Donated more than 500 mL of blood in the previous 56 days (based on the Canadian Blood Services guideline for blood donation.
  • Difficulty fasting or consuming the standard meals.
  • Do not tolerate venipuncture.
  • Unable to read or sign the ICF.

Treatment and study plan

Tamsulosin

Drug

Test 0.4 mg Capsule

Primary outcomes

  1. Cmax (Maximum Observed Concentration of Drug Substance in Plasma)

    Time frame: Blood samples drawn over 60 hour period

    Bioequivalence based on Cmax

  2. AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

    Time frame: Blood samples drawn over 60 hour period

    Bioequivalence based on AUC0-t

  3. AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

    Time frame: Blood samples drawn over 60 hour period

    Bioequivalence based on AUC0-inf

Sponsors and collaborators

Lead sponsor

Teva Pharmaceuticals USA

Industry

Registry information

Official study title

A Single-Dose, Comparative Bioavailability Study of Two Formulations of Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions

Important dates

Study start
2004
Primary completion
2004
Study completion
2004
First posted
Jun 23, 2010
Registry last updated
Aug 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.